Funding will enable Drs. Yves St-Pierre, David Chatenet, and Nicolas Doucet to develop a revolutionary immunotherapy against breast cancer.
Category: Press Release
Founded in 2015, GlycoNet has been working to develop a collaborative national network to accelerate carbohydrate-based healthcare treatments, vaccine, and technologies for Canadians.
The Networks of Centres of Excellence (NCE) announced today the renewed funding for five NCE networks.
The biopharmaceutical company founded by GlycoNet Investigator is working to develop a semi-synthetic vaccine in the preclinical phase
48Hour Discovery aims to develop clinically useful compounds by December 2020.
The partnership will support the development of novel technologies in drug discovery, accelerate scientific talents across Canada, and advance Canada’s position as an international leader for healthcare innovation.
The partnership will significantly enrich GlycoNet’s and API’s capacities to support companies with innovations in glycomics.
GlycoNet researchers discovered a molecule against Methicillin-resistant (MRSA) bacteria.
Projects seek solutions to health issues including heart disease, infections, cancer and diabetes
As the province’s leadership in glycomics research grows, investigators continue to work to answer important questions about human and animal health